LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,193
تعداد مقالات10,879
تعداد مشاهده مقاله73,424,730
تعداد دریافت فایل اصل مقاله20,539,832
Sabouri, Samaneh, Haem, Elham, Masoumpour, Masoumeh, Lemij, Hans G., Vermeer, Koenraad A., Yousefi, Siamak, Pourahmad, Saeedeh. (1404). Joint Modeling of Longitudinal Visual Field Changes and Time to Detect Progression in Glaucoma Patients: A Secondary Data Analysis. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/ijms.2024.103667.3699
Samaneh Sabouri; Elham Haem; Masoumeh Masoumpour; Hans G. Lemij; Koenraad A. Vermeer; Siamak Yousefi; Saeedeh Pourahmad. "Joint Modeling of Longitudinal Visual Field Changes and Time to Detect Progression in Glaucoma Patients: A Secondary Data Analysis". سامانه مدیریت نشریات علمی, , , 1404, -. doi: 10.30476/ijms.2024.103667.3699
Sabouri, Samaneh, Haem, Elham, Masoumpour, Masoumeh, Lemij, Hans G., Vermeer, Koenraad A., Yousefi, Siamak, Pourahmad, Saeedeh. (1404). 'Joint Modeling of Longitudinal Visual Field Changes and Time to Detect Progression in Glaucoma Patients: A Secondary Data Analysis', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/ijms.2024.103667.3699
Sabouri, Samaneh, Haem, Elham, Masoumpour, Masoumeh, Lemij, Hans G., Vermeer, Koenraad A., Yousefi, Siamak, Pourahmad, Saeedeh. Joint Modeling of Longitudinal Visual Field Changes and Time to Detect Progression in Glaucoma Patients: A Secondary Data Analysis. سامانه مدیریت نشریات علمی, 1404; (): -. doi: 10.30476/ijms.2024.103667.3699

Joint Modeling of Longitudinal Visual Field Changes and Time to Detect Progression in Glaucoma Patients: A Secondary Data Analysis

Iranian Journal of Medical Sciences
مقالات آماده انتشار، اصلاح شده برای چاپ، انتشار آنلاین از تاریخ 19 خرداد 1404    اصل مقاله (466.21 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2024.103667.3699
نویسندگان
Samaneh Sabouri1؛ Elham Haem2؛ Masoumeh Masoumpour3؛ Hans G. Lemij4؛ Koenraad A. Vermeer4؛ Siamak Yousefi5؛ Saeedeh Pourahmad* 2، 6
1Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4Rotterdam Ophthalmic Institute, the Rotterdam Eye Hospital, Rotterdam, Netherlands
5Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
6Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Glaucoma causes irreversible damage to the optic nerve and can lead to blindness if it is not treated appropriately. Evaluation of longitudinal changes in the visual field (VF) and detecting progression in a timely manner are critical for effective disease management. This study aimed to identify factors associated with VF impairment and disease progression using a Bayesian joint model. 
Methods: A total of 129 glaucoma patients (228 eyes) were recruited from an ongoing cohort study initiated in 1998 at the Rotterdam Eye Hospital in the Netherlands. Standard Automated Perimetry (SAP) was performed for each patient at regular 6-month follow-up intervals. Covariates included sex, age at baseline, mean intraocular pressure (IOP), and disease severity. A Bayesian joint model was employed, integrating a linear mixed effects model (LMM) for longitudinal mean deviation (MD) values and a Cox proportional hazards model for progression time. The statistical analyses were conducted using R software and the ‘JMbayes2’ package.
Results: Progression was observed in 33.8% of eyes. A significant association was found between MD changes and progression risk (α=-0.39, P<0.001). Older age (P=0.01), early-stage disease (P<0.001), and higher mean IOP (P<0.001) were associated with an increased risk of progression.
Conclusion: Considering longitudinal MD changes, age at baseline, mean IOP, and disease severity were significantly associated with the time to progression detection. Sex was not found to be a significant factor in glaucoma progression. 

تازه های تحقیق

Samaneh Sabouri (Google Scholar)

Saeedeh Pourahmad (Google Scholar)

کلیدواژه‌ها
Glaucoma؛ Joint model؛ Longitudinal studies؛ Disease progression؛ Survival analysis
مراجع
  1. Biggerstaff KS, Lin A. Glaucoma and Quality of Life. Int Ophthalmol Clin. 2018;58:11-22. doi: 10.1097/IIO.0000000000000230. PubMed PMID: 29870407.
  2. Gazzard G, Kolko M, Iester M, Crabb DP, Educational Club of Ocular S, Glaucoma M. A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients. J Glaucoma. 2021;30:732-43. doi: 10.1097/IJG.0000000000001889. PubMed PMID: 34049352; PubMed Central PMCID: PMCPMC8366599
  3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081-90. doi: 10.1016/j.ophtha.2014.05.013. PubMed PMID: 24974815.
  4. Usgaonkar UPS, Naik R, Shetty A. The economic burden of glaucoma on patients. Indian J Ophthalmol. 2023;71:560-6. doi: 10.4103/ijo.IJO_1676_22. PubMed PMID: 36727360; PubMed Central PMCID: PMCPMC10228918.
  5. Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89:1245-9. doi: 10.1136/bjo.2005.067355. PubMed PMID: 16170109; PubMed Central PMCID: PMCPMC1772870.
  6. Fu DJ, Ademisoye E, Shih V, McNaught AI, Khawaja AP. Burden of Glaucoma in the United Kingdom: A Multicenter Analysis of United Kingdom Glaucoma Services. Ophthalmol Glaucoma. 2023;6:106-15. doi: 10.1016/j.ogla.2022.08.007. PubMed PMID: 35973529.
  7. Maiouak M, Taybi HEO, Berraho M, Abdellaoui M, El Fakir S, Andaloussi IB, et al. Medical Direct Cost of Glaucoma in Morocco. Open Access Library Journal. 2023;10:1-10. doi: 10.4236/oalib.1110001.
  8. Sabouri S, Pourahmad S, Vermeer KA, Lemij HG, Yousefi S. Pointwise and Region-Wise Course of Visual Field Loss in Patients With Glaucoma. Transl Vis Sci Technol. 2022;11:20. doi: 10.1167/tvst.11.7.20. PubMed PMID: 35877094; PubMed Central PMCID: PMCPMC9339695.
  9. Bryan S [Internet]. Prediction of Visual Prognosis to Optimize Frequency of Perimetric Testing in Glaucoma. [cited 4 October 2017]. Available from: https://repub.eur.nl/pub/101802/
  10. Bryan SR, Vermeer KA, Eilers PH, Lemij HG, Lesaffre EM. Robust and censored modeling and prediction of progression in glaucomatous visual fields. Invest Ophthalmol Vis Sci. 2013;54:6694-700. doi: 10.1167/iovs.12-11185. PubMed PMID: 24030462.
  11. Kim JH, Rabiolo A, Morales E, Yu F, Afifi AA, Nouri-Mahdavi K, et al. Risk Factors for Fast Visual Field Progression in Glaucoma. Am J Ophthalmol. 2019;207:268-78. doi: 10.1016/j.ajo.2019.06.019. PubMed PMID: 31238025.
  12. Liebmann K, De Moraes CG, Liebmann JM. Measuring Rates of Visual Field Progression in Linear Versus Nonlinear Scales: Implications for Understanding the Relationship Between Baseline Damage and Target Rates of Glaucoma Progression. J Glaucoma. 2017;26:721-5. doi: 10.1097/IJG.0000000000000710. PubMed PMID: 28692594; PubMed Central PMCID: PMCPMC5565841.
  13. Fujino Y, Asaoka R, Murata H, Miki A, Tanito M, Mizoue S, et al. Evaluation of Glaucoma Progression in Large-Scale Clinical Data: The Japanese Archive of Multicentral Databases in Glaucoma (JAMDIG). Invest Ophthalmol Vis Sci. 2016;57:2012-20. doi: 10.1167/iovs.15-19046. PubMed PMID: 27127924.
  14. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-13. doi: 10.1001/archopht.120.6.701. PubMed PMID: 12049574.
  15. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-79. doi: 10.1001/archopht.120.10.1268. PubMed PMID: 12365904.
  16. Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295-304. doi: 10.1016/S0140-6736(14)62111-5. PubMed PMID: 25533656.
  17. Wu Z, Saunders LJ, Daga FB, Diniz-Filho A, Medeiros FA. Frequency of Testing to Detect Visual Field Progression Derived Using a Longitudinal Cohort of Glaucoma Patients. Ophthalmology. 2017;124:786-92. doi: 10.1016/j.ophtha.2017.01.027. PubMed PMID: 28268099.
  18. Rizopoulos D. Joint models for longitudinal and time-to-event data. New York: CRC press; 2012. doi: 10.1201/b12208.
  19. ROD-REP [Internet]. Rotterdam Ophthalmic Data Repository. [cited 30 July 2024]. Available from: http://www.rodrep.com/longitudinal-glaucomatous-vf-data---description.html
  20. Swaminathan SS, Berchuck SI, Jammal AA, Rao JS, Medeiros FA. Rates of Glaucoma Progression Derived from Linear Mixed Models Using Varied Random Effect Distributions. Transl Vis Sci Technol. 2022;11:16. doi: 10.1167/tvst.11.2.16. PubMed PMID: 35138343; PubMed Central PMCID: PMCPMC8842468
  21. Kleinbaum DG, Klein M. Survival analysis a self-learning text. Berlin: Springer; 1996. doi: 10.2307/2532873.
  22. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New Jersey: John Wiley & Sons; 2012. doi: 10.1002/9781119513469.
  23. Pathak M, Demirel S, Gardiner SK. Nonlinear, multilevel mixed-effects approach for modeling longitudinal standard automated perimetry data in glaucoma. Invest Ophthalmol Vis Sci. 2013;54:5505-13. doi: 10.1167/iovs.13-12236. PubMed PMID: 23833069; PubMed Central PMCID: PMCPMC3747790.
  24. Rizopoulos D. The R package JMbayes for fitting joint models for longitudinal and time-to-event data using MCMC. Journal of statistical software. 2016;72:1-46.
  25. Anjullo BB, Kumaso SK, Erango MA. Joint modeling of longitudinal change in pulse rate and survival time of heart failure patients treated at Arbaminch General Hospital, Southern Ethiopia. PLoS One. 2023;18:e0282637. doi: 10.1371/journal.pone.0282637. PubMed PMID: 36881600; PubMed Central PMCID: PMCPMC9990934.
  26. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56. doi: 10.1001/archopht.121.1.48. PubMed PMID: 12523884.
  27. Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. The american statistician. 2004;58:16-24. doi: 10.1198/0003130042854.
  28. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Stat Med. 2007;26:2813-35. doi: 10.1002/sim.2749. PubMed PMID: 17124698; PubMed Central PMCID: PMCPMC2586033.
  29. Ye X, She X, Shen L. Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017. Acta Ophthalmol. 2020;98:e593-e8. doi: 10.1111/aos.14330. PubMed PMID: 31912656.
  30. Vajaranant TS, Nayak S, Wilensky JT, Joslin CE. Gender and glaucoma: what we know and what we need to know. Curr Opin Ophthalmol. 2010;21:91-9. doi: 10.1097/ICU.0b013e3283360b7e. PubMed PMID: 20051857; PubMed Central PMCID: PMCPMC4326058.
  31. Qiu Y, Yu J, Tang L, Ren J, Shao M, Li S, et al. Association Between Sex Hormones and Visual Field Progression in Women With Primary Open Angle Glaucoma: A Cross-Sectional and Prospective Cohort Study. Front Aging Neurosci. 2021;13:756186. doi: 10.3389/fnagi.2021.756186. PubMed PMID: 35002675; PubMed Central PMCID: PMCPMC8741302.
  32. Douglass A, Dattilo M, Feola AJ. Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma. Cell Mol Neurobiol. 2023;43:79-97. doi: 10.1007/s10571-021-01179-z. PubMed PMID: 34981287; PubMed Central PMCID: PMCPMC9250947.
  33. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53. doi: 10.1016/j.survophthal.2008.08.006. PubMed PMID: 19038621.
  34. Radcliffe NM, Alvarez-Ascencio D. Update on Risk Factors for Glaucoma Progression. Glaucoma Physician. 2018;22:36-40.
  35. Park HL, Hong KE, Park CK. Impact of Age and Myopia on the Rate of Visual Field Progression in Glaucoma Patients. Medicine (Baltimore). 2016;95:e3500. doi: 10.1097/MD.0000000000003500. PubMed PMID: 27227916; PubMed Central PMCID: PMCPMC4902340.
  36. Zhou K, Shang X, Wang XY, Wang XJ, Cheng HH, Hu HS, et al. [Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area]. Zhonghua Yan Ke Za Zhi. 2019;55:777-84. doi: 10.3760/cma.j.issn.0412-4081.2019.10.009. PubMed PMID: 31607067.
  37. Matlach J, Bender S, Konig J, Binder H, Pfeiffer N, Hoffmann EM. Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression. Clin Ophthalmol. 2019;13:9-16. doi: 10.2147/OPTH.S186526. PubMed PMID: 30587914; PubMed Central PMCID: PMCPMC6302802.
  38. Sakata R, Yoshitomi T, Iwase A, Matsumoto C, Higashide T, Shirakashi M, et al. Factors Associated with Progression of Japanese Open-Angle Glaucoma with Lower Normal Intraocular Pressure. Ophthalmology. 2019;126:1107-16. doi: 10.1016/j.ophtha.2018.12.029. PubMed PMID: 30605741.
  39. Germano RAS, Germano CS, Susanna FN, Susanna R. Patterns of Visual Field Loss in Early, Moderate, and Severe Stages of Open Angle Glaucoma. J Glaucoma. 2022;31:609-13. doi: 10.1097/IJG.0000000000001986. PubMed PMID: 35019874.
  40. Maul EJ, Kastner A, Schmidt J, Tapia JA, Morales C, Maul EA. Visual field progression in patients with severe glaucoma. Graefes Arch Clin Exp Ophthalmol. 2021;259:1579-86. doi: 10.1007/s00417-020-05036-5. PubMed PMID: 33417091.
آمار
تعداد مشاهده مقاله: 16
تعداد دریافت فایل اصل مقاله: 3


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب